Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

ClinicalTrials.gov ID: NCT02839200

Public ClinicalTrials.gov record NCT02839200. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multi-center, Double-blind, Randomized, Placebo-controlled, Active-reference, Parallel-group, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.

Study identification

NCT ID
NCT02839200
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Enrollment
360 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 64 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 3, 2016
Primary completion
Apr 11, 2017
Completion
Jun 19, 2017
Last update posted
Apr 12, 2020

2016 – 2017

United States locations

U.S. sites
15
U.S. states
9
U.S. cities
15
Facility City State ZIP Site status
Investigator Site Santa Monica California 90404
Investigator Site Upland California 91786
Investigator Site Brandon Florida 33511
Investigator Site Clearwater Florida 33765
Investigator Site Coral Gables Florida 33134
Investigator Site DeLand Florida 32720
Investigator Site Hollywood Florida 33024
Investigator Site Miami Florida 33143
Investigator Site Atlanta Georgia 30342
Investigator Site Chicago Illinois 60634
Investigator Site Indianapolis Indiana 46250
Investigator Site Novi Michigan 48377
Investigator Site Las Vegas Nevada 89104
Investigator Site New York New York 10019
Investigator Site Cincinnati Ohio 45255

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02839200, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2020 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02839200 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →